GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rock Creek Pharmaceuticals Inc (OTCPK:RCPIQ) » Definitions » Net Change in Cash

Rock Creek Pharmaceuticals (Rock Creek Pharmaceuticals) Net Change in Cash : $-2.81 Mil (TTM As of Jun. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Rock Creek Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Rock Creek Pharmaceuticals's Net Change in Cash for the three months ended in Jun. 2016 was $-0.37 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2016 was $-2.81 Mil.

Rock Creek Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Rock Creek Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rock Creek Pharmaceuticals Net Change in Cash Chart

Rock Creek Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.01 13.05 -19.24 -3.49 0.10

Rock Creek Pharmaceuticals Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.90 -2.85 0.35 0.06 -0.37

Rock Creek Pharmaceuticals Net Change in Cash Calculation

Rock Creek Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2015 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-7.393+0.273+7.218+0
=0.10

Rock Creek Pharmaceuticals's Net Change in Cash for the quarter that ended in Jun. 2016

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.547+0+1.18+0
=-0.37

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rock Creek Pharmaceuticals Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Rock Creek Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Rock Creek Pharmaceuticals (Rock Creek Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rock Creek Pharmaceuticals Inc (OTCPK:RCPIQ) » Definitions » Net Change in Cash
Comparable Companies
ASX:MEB SNNA XCNQ:PREV GEMP INTI ADYX EARS PHIO TSXV:RP XCNQ:NSHS BOM:511509 WAR:BLR CBLI BOM:524663 ASX:FIJ GNPX INSYQ OSTO:ANNX LSE:NSCI XBIO
Traded in Other Exchanges
N/A
Address
2040 Whitfield Avenue, Suite 300, Sarasota, FL, USA, 34243
Website
http://www.rockcreekpharmaceuticals.com
Rock Creek Pharmaceuticals Inc is engaged in research, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders, utilizing its proprietary compounds. The company is focusing its drug development efforts on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its proprietary formulations of its lead compound anatabine citrate. Its objective is to develop, obtain approval for, and commercialize pharmaceutical products utilizing its anatabine-based and related compounds.
Executives
Lee M Canaan director 20101 HOOVER RD, DETROIT MI 48205
Naomi Whittel director C/O STAR SCIENTIFIC, INC., 4470 COX ROAD, SUITE 110, GLEN ALLEN VA 23060
Ralph B Everett director 1299 PENNSYLVANIA AVE NW, 10TH FL, WASHINGTON DC 20004-2400
Richard L Sharp director C/O CIRCUIT CITY STORES, 9950 MAYLAND DRIVE, RICHMOND VA 23233
Marc D Oken director C/O FALFURRIAS CAPITAL PARTNERS, 100 N. TRYON STREET, SUITE 5120, CHARLOTTE NC 28202
Odonnell Kathleen M Tr Irrev Tr 1 Fbo Francis E Odonnell Jr other: former 10% owner
David C Vorhoff director C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Christopher G Miller officer: Chief Financial Officer 801 LIBERTY WAY CHESTER VA 23836

Rock Creek Pharmaceuticals (Rock Creek Pharmaceuticals) Headlines

From GuruFocus

Star Scientific Inc. (STSI) CFO Park A Iii Dodd buys 10,000 Shares

By GuruFocus Research GuruFocus Editor • 11-18-2009

Star Scientific Inc. (STSI) President & COO Paul L Perito buys 30,000 Shares

By GuruFocus Research GuruFocus Editor • 11-13-2009

Star Scientific Inc. (STSI) President & COO Paul L Perito buys 20,000 Shares

By GuruFocus Research GuruFocus Editor • 11-16-2009